Jonathan Dowell, M.D.
Program Director, Hematology Oncology Fellowship Program
Department Internal Medicine
You have reached the Academic Profile.
For more information on the doctor and patient care, please visit the clinical profile.View Clinical Profile
Jonathan Dowell, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern, and a member of its Division of Hematology and Oncology. He is Program Director of the Hematology Oncology Fellowship Program. He also serves as Chief of Hematology/Oncology at the Dallas VA Medical Center.
Dr. Dowell specializes primarily in thoracic malignancies, including non-small cell and small cell lung cancers, mesothelioma, and thymoma.
Dr. Dowell earned his bachelor’s degree magna cum laude in neuroscience from Amherst College. He received his medical degree from the University of Chicago’s Pritzker School of Medicine and completed internal medicine residency training at UT Southwestern He completed advanced training through a fellowship in hematology/oncology at Vanderbilt University.
Certified by the American Board of Internal Medicine in hematology and in oncology, he joined the UT Southwestern Faculty in 1996.
Dr. Dowell’s research interests include thoracic malignancies. His investigations have resulted in 40 publications in peer-reviewed journals and contributions to more than 30 book chapters, reviews, editorials, and case reports. Additionally, he has presented his findings at scientific conferences throughout the United States and internationally.
At UT Southwestern, Dr. Dowell chairs the SImmons Cancer Center Data and Safety Monitoring Committee, and co-chairs the Dallas VA Transfusion Utilization Committee and the Veterans Integrated Service Network 17 Hematology/Oncology Work Group.
Dr. Dowell is active in several professional societies, including the American Society of Clinical Oncology, the American Society of Hematology, the Texas Medical Association, and the Dallas County Medical Society.
In 2018, he was named a Super Doctor by Texas Monthly.
His interests outside of work include travel, baseball, and family activities.
- Medical School
- University of Chicago Pritzker School of Medicine (1993)
- UT Southwestern Medical Center (1994), Internal Medicine
- UT Southwestern Medical Center (1996), Internal Medicine
- Vanderbilt University Medical Center (2000), Hematology Oncology
- Upper Extremity Venous Thrombosis in Patients With Cancer With Peripherally Inserted Central Venous Catheters: A Retrospective Analysis of Risk Factors
- Ahn DH, Illum HB, Wang DH, Sharma A, and Dowell JE JOP 2013 5
- A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
- Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL Lung Cancer 2012 Sep 77 3 567-71
- Consent timing and experience: modifiable factors that may influence interest in clinical research.
- Gerber DE, Rasco DW, Skinner CS, Dowell JE, Yan J, Sayne JR, Xie Y J Oncol Pract 2012 Mar 8 2 91-6
- ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation.
- Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE Anticancer Res. 2011 Dec 31 12 4135-9
- Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy.
- Gerber DE, Rasco DW, Le P, Yan J, Dowell JE, Xie Y J Thorac Oncol 2011 Feb 6 2 365-71
- Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.
- Rasco DW, Yan J, Xie Y, Dowell JE, Gerber DE J Thorac Oncol 2010 Oct 5 10 1529-35
- Small cell lung cancer: are we making progress?
- Dowell JE Am. J. Med. Sci. 2010 Jan 339 1 68-76
- The impact of consenter characteristics and experience on patient interest in clinical research.
- Rasco DW, Xie Y, Yan J, Sayne JR, Skinner CS, Dowell JE, Gerber DE Oncologist 2009 May 14 5 468-75
- Small-cell lung cancer: translational research enroute to therapeutic advances.
- Dowell J, Minna JD Oncology (Williston Park, N.Y.) 2008 Nov 22 13 1493, 1495
- Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer.
- Dudek AZ, Larson T, McCleod MJ, Schneider DJ, Dowell JE, Banerjee TK, Pandya KJ, Bromund JL, Chen R, Monberg MJ, Obasaju CK J Thorac Oncol 2008 Apr 3 4 394-9
Honors & Awards
- Internal Medicine, Core Clerkship Teaching Award
Teaching Award (2012)
- Eugene P. Frenkel Outstanding Teaching Award
Teaching Award (2010)
Merit Award (2000)
- Vanderbilt Hematology/Oncology
Fellow Award (1998)
- American Society of Clinical Oncology
- American Society of Hematology